Use of Nucleoside (Tide) Analogues in Patients with Hepatitis B-Related Acute Liver Failure
Open accessThe DOI matches its Crossref record.
Abstract
Background and AimsThe efficacy of nucleoside(tide) analogues (NA) in the treatment of acute liver failure due to hepatitis B virus (HBV-ALF) remains controversial. We determined retrospectively the impact of NAs in a large cohort of patients with HBV-ALF.MethodsThe US Acute Liver Failure Study Group, a 23-site registry, prospectively enrolled 1,413 patients with ALF with different etiologies between 1998 and 2008. Of those, 105 patients were identified as HBV-ALF patients, of whom we excluded those without data on NA use or with co-infection with hepatitis C, leaving 85 patients, 43 of whom had received NA treatment. HBV-DNA on admission was quantified by real time polymerase chain reaction.ResultsThe treated and untreated groups were similar in most respects but differed significantly in regard to higher aminotransferase and bilirubin levels and hepatic coma grades, all being observed in the untreated group. Median duration of NA treatment was 6 days (range, 1–21 days). Overall survival in the NA treated and untreated groups were 61 and 64%, respectively (P = 0.72). Rates of transplant-free survival were 21 and 36% in the treated and untreated groups, respectively (P = 0.42). Multivariate analysis revealed that not using a NA [odds ratio (OR) 4.4, 95% CI 1.1–18.1, P = 0.041], hepatic coma grade I or II [OR 14.4, 95% CI 3.3–62.8, P < 0.001] and prothrombin time (PT) [OR 0.59, 95% CI 0.39–0.89, P = 0.012] were predictors of improved transplant-free survival.ConclusionsPatients who are admitted with established HBV-ALF do not appear to benefit from viral suppression using nucleoside(tide) analogues presumably because of rapid disease evolution and short treatment duration. Despite the lack of benefit, NAs should still be given to transplantation candidates since viral suppression prevents recurrence after grafting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure
Wendon, J., Cordoba, J., Dhawan, A., Larsen, F. S., Manns, M., Nevens, F., Samuel, D., Simpson, K. J., Yaron, I., & Bernardi, M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.12.003 · Cited by 917
Stravitz, R. T., & Lee, W. M. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31894-x · Cited by 844
Self-citationManagement of Acute Liver Failure: Update 2022
Tujios, S., Stravitz, R. T., & Lee, W. M. (2022) · Seminars in Liver Disease · doi:10.1055/s-0042-1755274 · Cited by 117
Self-citation
Metadata
- Authors
- The Acute Liver Failure Study Group, Dao, D. Y., Seremba, E., Ajmera, V., Sanders, C., Hynan, L. S., & Lee, W. M.
- Venue
- Digestive Diseases and Sciences
- Published
- 2011-12-25
- Volume
- 57
- Issue
- 5
- Pages
- 1349-1357
- ISSN
- 0163-2116 (ISSN-L)
- 1573-2568
- OpenAlex
- W2078628061
- Cited by
- 39
- References
- 0
- FWCI
- 1.44
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of Nucleoside (Tide) Analogues in Patients with Hepatitis B-Related Acute Liver Failure. https://app.cochat.ai/papers/10.1007/s10620-011-2013-3
- The paper
- The Acute Liver Failure Study Group, Dao, D. Y., Seremba, E., Ajmera, V., Sanders, C., Hynan, L. S., & Lee, W. M. (2012). Use of Nucleoside (Tide) Analogues in Patients with Hepatitis B-Related Acute Liver Failure. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-011-2013-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.